Kanvas Biosciences raises $12.5M, increasing total funding to $29.5M, to advance its microbiome platform and lead drug candidate, KAN-001, in cancer therapy.
Kanvas Biosciences, a spatial biology company, raises $12.5M, totaling $29.5M, led by DCVC and Lions Capital. The Princeton-based firm develops a microbiome drug screening, discovery, and manufacturing platform for live biotherapeutics. The funding will advance their lead drug candidate, KAN-001, in cancer therapy by altering a patient's microbiome, and expand their platform to other therapeutic areas.
July 01, 2024
3 Articles